Mortality risk prediction in high-risk patients undergoing coronary artery bypass grafting: Are traditional risk scores accurate?

Maxim Goncharov, Omar Asdrúbal Vilca Mejía, Camila Perez de Souza Arthur, Bianca Maria Maglia Orlandi, Alexandre Sousa, Marco Antônio Praça Oliveira, Fernando Antibas Atik, Rodrigo Coelho Segalote, Marcos Gradim Tiveron, Pedro Gabriel Melo de Barros e Silva, Marcelo Arruda Nakazone, Luiz Augusto Ferreira Lisboa, Luis Alberto Oliveira Dallan, Zhe Zheng, Shengshou Hu, Fabio Biscegli Jatene

ABSTRACT

Background
The performance of traditional scores is significantly limited to predict mortality in high-risk cardiac surgery. The aim of this study was to compare the performance of STS, ESII and HiriSCORE models in predicting mortality in high-risk patients undergoing CABG.

Methods
Cross-sectional analysis in the international prospective database of high-risk patients: HiriSCORE project. We evaluated 248 patients with STS or ESII (5–10%) undergoing CABG in 8 hospitals in Brazil and China. The main outcome was mortality, defined as all deaths occurred during the hospitalization in which the operation was performed, even after 30 days. Five variables were selected as predictors of mortality in this cohort of patients. The model’s performance was evaluated through the calibration-in-the-large and the receiver operating curve (ROC) tests.

Results
The mean age was 69.90±9.45, with 52.02% being female, 25% of the patients were on New York Heart Association (NYHA) class IV and 49.6% had Canadian Cardiovascular Society (CCS) class 4 angina, and 85.5% had urgency or emergency status. The mortality observed in the sample was 13.31%. The HiriSCORE model showed better calibration (15.0%) compared to ESII (6.6%) and the STS model (2.0%). In the ROC curve, the
HiriSCORE model showed better accuracy (ROC = 0.74) than the traditional models STS (ROC = 0.67) and ESII (ROC = 0.50).

Conclusion
Traditional models were inadequate to predict mortality of high-risk patients undergoing CABG. However, the HiriSCORE model was simple and accurate to predict mortality in high-risk patients.

Introduction
Over time, cardiovascular surgery results have progressively improved. One of the reasons for the improvement is associated with the risk stratification brought by risk scores and perioperative optimization [1]. In a continuous search for excellence, the application of ever more accurate score models is essential, especially in the evaluation of indications for new cost-effective procedures [2]. In addition, it is necessary to fully inform each patient about the risks associated with this procedure, which should be adjusted to the results of the hospital [3].

In this scenario, several models have been built and validated, aiming to reach more accurate predictions for specific populations. Among these models, STS [4] and ESII [5] reverberate the most and, at the same time, are supported by international guidelines. Both are recommended for patients undergoing most cardiovascular procedures. STS' greatest advantage over ESII is probably the sample size, which is updated periodically. At the same time, one of the biggest criticisms of this voluntary registry may be related to estimated values unreachable for other populations [6]. It is known that the results of mandatory registries, which include all operated patients, can have high deviation [7]. In underdeveloped or developing countries, the evaluation provided by these tools can be impaired, due to the measurement of only part of the treatment, not the health system [8].

Even with the improvement of registry systems and refinement in formulation techniques of those tools, predictions are still impaired, especially in the high-risk subgroup [9, 10]. This may be related to the small number of high-risk patients included in the registries that originated the traditional models. In this aspect, traditional models would be important for a first categorization (approximation), but not for defining exactly what happens to patients at higher risk of death after cardiac surgery, as supported by the evidence. Therefore, this new model would be a second step and would come to a more accurate decision-making, through the recalibration and remodeling of variables for the high-risk population.

In this scenario, we evaluated the performance of STS, ESII and the HiriSCORE model derived from high-risk patients undergoing CABG (https://clinicaltrials.gov/ct2/show/NCT02560285).

Methods
Ethics and consent form
This study is a sub-analysis belonging to the project entitled "High-risk Patients in Cardiac Surgery Procedures: HiriSCORE", registered online under number 13795, submitted and approved by the HCFMUSP Ethics Commission for Analysis of Research Projects (CAPPesq) as SDC: 4256/15/083.
Sample

The cross-sectional analysis is part of the HiriSCORE Project and coordinated by the Cardiac Surgery department of "Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo" (InCor-HCFMUSP). All cases were consecutively operated from April 2016 to August 2019. Data came from 8 hospitals in Brazil (7) and China (1):

1. Instituto do Coração, HCFMUSP, São Paulo, SP, Brazil.
2. Hospital de Base de São José do Rio Preto, SP, Brazil.
3. Instituto Nacional de Cardiologia do Rio de Janeiro, RJ, Brazil.
4. Fuwai Hospital, Beijing, China.
5. Hospital Beneficência Portuguesa, SP, Brazil.
6. Hospital Santa Casa de Marilia, SP, Brazil.
7. Hospital Samaritano Paulista, SP, Brazil.
8. Instituto de Cardiologia do Distrito Federal, DF, Brazil.

The total sample consisted of 19,786 patients who underwent CABG, 11,692 of whom underwent isolated CABG. For this analysis, we have selected 248 patients considered at high risk (Fig 1). The final cohort included 248 patients (222 patients from Brazil and 26 patients from Fuwai Hospital in China) who underwent CABG with a mortality risk of 5 to 10% predicted by ESII (S1 Table).

Inclusion and exclusion criteria

**Inclusion criteria.** Patients aged 18 years or older who underwent isolated CABG and with mortality expected by EuroSCORE II between 5 and 10%

**Exclusion criteria.** Patients undergoing any other cardiac procedures than CABG. To have a more homogeneous sample for the construction of the HiriSCORE model, 4 patients with EuroSCORE II > 10% were excluded.

There were no cases of MIDCAB or OPCAB in the studied sample.

Collecting, defining and organizing data

This analysis was made in the HiriSCORE Project database (https://clinicaltrials.gov/ct2/show/NCT02560285). It is a prospective multicenter and international registry. Data were collected by people trained for this purpose in each participating center and incorporated online on the REDCap platform (https://redcap.hc.fm.usp.br) through three interfaces available online: pre-operative, intraoperative, and post-operative. Truthfulness and completeness of data were supervised by the registry’s executive committee. Variable definitions were adopted to respond to ESII (http://euroscore.org/calc.html) and STS (http://riskcalc.sts.org/stswebriskcalc/#/calculate) calculations. The outcome analyzed was mortality, defined as all deaths that occurred during the hospitalization in which the operation was performed, even after 30 days.

Statistical analysis

The analysis was performed using the statistical software STATA version 13.1 (StataCorp, Texas, USA) for MacOS. To assess the distribution of the data, the Shapiro-Wilk test and homogeneity between groups were performed. Continuous variables were expressed as
mean ± standard deviation and categorical variables as absolute and relative frequencies. The association between mortality and the predictors was verified by the Chi-square and Fisher’s exact tests for the contingency tables. For the prediction of in-hospital mortality, stepwise multivariate logistic regression analysis was verified. The elaboration of the HiriSCORE was performed using stepwise multivariate logistic regression, with the pre- and intra-operative predictors, in which the risk value (OR) may vary according to the sum of variables that represent risk. All variables with inclusion criteria in the score were described in the results and expressed in a table with a coefficient value, 95% CI and p-value. The performance of the ESII and STS models was measured by comparing the mortality observed in the current study with the mortality predicted by the models in the established risk groups. Therefore, to assess the ability of ESII and STS to identify the risk of individuals included in the current study, the calibration-in-the-large curve and the discrimination by area under the ROC curve were performed. P-values of <0.05 were considered significant and plausible variables were identified.
as predictors of mortality after cardiac procedures. For internal validation of the HirisciORE model, the method of discrimination by area under the ROC curve and calibration-in-the-large was selected.

Results
Overall, Table 1 includes data of 248 patients who underwent CABG surgery. The average age was 69.9±9.45y (95% CI 68–70). Most patients were female (52%). There was a high prevalence of prior myocardial infarction (74%), hypertension (85%) and urgent or emergency surgery (85%). Eighty-one percent of patients had three-vessel coronary artery disease.

Table 1. Description of variables used in high-risk CABG database.

| Variables                                      | Total (n = 248) | 95% CI   |
|------------------------------------------------|----------------|----------|
| Age (years)                                   | 69.90 ± 9.45   | 68.55–70.90 |
| Body mass index (kg/m²)                       | 26.11 ± 4.55   | 25.50–26.60 |
| Systolic pulmonary artery pressure (mmHg)     | 27.30 ± 13.30  | 25.70–29.00 |
| Left ventricle ejection fraction (%)          | 46.00 ± 14.80  | 43.90–47.60 |
| Glucose (mg/dL)                                | 152.00 ± 78.00 | 140.7–161.16 |
| Creatinine (mg/dL)                            | 1.52 ± 1.10    | 1.37–1.64 |
| Gender (male)                                 | 119            | 47.98    |
| Hypertension                                  | 212            | 85.48    |
| Peripheral arterial disease                   | 49             | 19.76    |
| Dialysis                                      | 4              | 1.61     |
| Cerebrovascular disease                       | 73             | 29.44    |
| Pre-operative intra-aortic balloon pump       | 50             | 20.16    |
| Pulmonary hypertension                        | 144            | 58.06    |
| Diabetes mellitus                             | 143            | 57.66    |
| Insulin control                               | 80             | 32.26    |
| COPD                                          | 59             | 23.79    |
| Atrial fibrillation:                          |                |          |
| Paroxysmal/persistent                         | 16             | 6.45     |
| Continued/permanent                           | 5              | 2.02     |
| Previous cardiac intervention:                |                |          |
| Previous PCI                                  | 43             | 17.34    |
| Previous CABG                                 | 9              | 3.63     |
| Previous valve surgery                        | 4              | 1.61     |
| Previous MI                                   | 184            | 74.19    |
| Three-vessel coronary artery disease          | 201            | 81.05    |
| Left main stenosis > 50%                      | 75             | 30.24    |
| NYHA IV                                       | 63             | 25.40    |
| CCS 4                                         | 123            | 49.60    |
| Moderate heart valve disease                  | 90             | 36.29    |
| Urgency or emergency status                   | 212            | 85.48    |
| Death                                         | 33             | 13.31    |

CABG: coronary artery bypass grafting; CCS: Canadian Cardiovascular Society; COPD: chronic obstructive pulmonary disease; MI: myocardial infarction; NYHA: New York Heart Association; PCI: percutaneous coronary intervention.

https://doi.org/10.1371/journal.pone.0255662.t001
disease. Almost half (49%) of the patients had unstable angina (CCS 4). The observed mortality reached 13%.

In the association analysis, all variables with a focus on preoperative variables were studied. The main variables of interest are shown in Table 2.

In the association analysis in the cohort selected to prepare the HiriSCORE model, the following variables were related to deaths: diabetes (p = 0.023); insulin-dependent diabetes (p = 0.024); lesion of the left main coronary artery > 50% (p = 0.014); moderate heart valve disease (p = 0.019); body mass index > 30 kg/m² (p = 0.02) and creatinine clearance < 30 mL/min (p = 0.002) (Table 2). These variables were selected for stepwise multivariate regression analysis to create the HiriSCORE model.

Table 2. Association analysis in the high-risk CABG database.

| Association                              | Deaths (n = 33) | Alive patients (n = 215) | p   |
|------------------------------------------|----------------|--------------------------|-----|
| Male gender                              | 16             | 13.4                     | 103 | 86.6 | 0.951 |
| Female gender                            | 17             | 13.2                     | 112 | 86.8 |       |
| Hypertension                             | 25             | 11.8                     | 187 | 88.2 | 0.88  |
| Peripheral artery disease                 | 5              | 10.2                     | 44  | 89.8 | 0.475 |
| Dialysis                                 | 0              | 0                        | 4   | 100  | 0.563 |
| Cerebrovascular disease                   | 5              | 6.8                      | 68  | 93.2 | 0.053 |
| Pulmonary hypertension                    | 17             | 11.8                     | 127 | 88.2 | 0.413 |
| Diabetes mellitus                         | 13             | 9.1                      | 130 | 90.9 | 0.023 |
| Insulin-dependent                         | 5              | 6.3                      | 75  | 93.8 | 0.024 |
| Without atrial fibrillation               | 28             | 12.3                     | 199 | 87.7 | 0.128 |
| Persistent/paroxysmal atrial fibrillation | 4              | 25                       | 12  | 75   |       |
| Continued/permanent atrial fibrillation   | 1              | 20                       | 4   | 80   |       |
| COPD                                     | 9              | 15.3                     | 50  | 84.7 | 0.614 |
| Previous PCI                             | 2              | 4.7                      | 41  | 95.3 | 0.047 |
| Previous CABG                            | 3              | 33.3                     | 6   | 66.7 | 0.103 |
| Previous valve procedure                  | 0              | 0                        | 4   | 100  | 0.563 |
| Previous MI                              | 22             | 12                       | 162 | 88   | 0.289 |
| Coronary disease                         | 32             | 13.2                     | 211 | 86.8 | 0.656 |
| Three-vessel coronary artery disease      | 30             | 14.9                     | 171 | 85.1 | 0.121 |
| Left main disease > 50%                   | 16             | 21.3                     | 59  | 78.7 | 0.014 |
| NYHA I                                   | 11             | 20                       | 44  | 80   | 0.323 |
| NYHA II                                  | 4              | 10.5                     | 34  | 89.5 |       |
| NYHA III                                 | 7              | 9.3                      | 68  | 90.7 |       |
| NYHA IV                                  | 10             | 15.9                     | 53  | 84.1 |       |
| CCS 4                                    | 14             | 11.4                     | 109 | 88.6 | 0.376 |
| Moderate heart valve disease              | 18             | 20                       | 72  | 80   | 0.019 |
| Urgency/emergency status                  | 31             | 14.6                     | 181 | 85.4 | 0.139 |
| Emergency                                | 2              | 20                       | 3   | 80   | 0.188 |
| Pre-operative IABP                       | 10             | 20                       | 40  | 80   | 0.119 |
| Body mass index > 30 kg/m²                | 9              | 25.7                     | 26  | 74.3 | 0.02  |
| Creatinine clearance < 30 mL/min          | 10             | 30.3                     | 23  | 69.7 | 0.002 |

CABG: coronary artery bypass grafting; CCS: Canadian Cardiovascular Society; COPD: chronic obstructive pulmonary disease; IABP: intra-aortic balloon pump; MI: myocardial infarction; NYHA: New York Heart Association; PCI: percutaneous coronary intervention.

https://doi.org/10.1371/journal.pone.0255662.t002
Elaboration of HiriSCORE model

After association analysis with subsequent multivariate logistic regression using data of 248 patients with predicted risk by ESII 5–10% undergoing CABG, 5 significant variables were determined: body mass index, creatinine clearance, left main coronary artery stenosis, moderate heart valve disease and glucose (Table 3).

The HiriSCORE risk calculator was developed based on the variables described above. The logistical formula for calculating the mortality risk is as follows:

$$RDM = \frac{\text{Exp} (\beta_0 + \sum \beta_i x_i)}{1 + \text{Exp} (\beta_0 + \sum \beta_i x_i)}$$

where RDM is the mortality risk, Exp is the exponential function, $\beta_0$ is the constant with value -3.623276, $\beta_i$ is the tabulated coefficient of the independent variable $x_i$.

Performance validation of ESII, STS and HiriSCORE models

Calibration of ESII, STS and HiriSCORE models. Table 4 shows that both traditional risk models underestimate mortality in high-risk patients, when the HiriSCORE model showed good performance in all 5 subgroups.

The expected mean mortality in the established groups (quintiles) by the HiriSCORE model was 15.0%, by the STS was 2.0% and by the ESII was 6.6% ($p < 0.05$). The expected mortality by ESII was > 3 times that of STS and < 2 times that of HiriSCORE (Fig 2).

The calibration-in-the-large showed that the expected mortality by STS (observed minus predicted [O−P] = 11.4) and ESII (O−P = 6.6) underestimated the mortality observed in high-risk patients undergoing CABG. However, the HiriSCORE model showed good calibration ($O−P = −0.2$).

Table 3. Elaboration of HiriSCORE model.

| Variables                              | Coef.    | 95% CI   | p     |
|----------------------------------------|----------|----------|-------|
| Body mass index > 30 kg/m$^2$          | 1.223577 | 0.26–2.18 | 0.013 |
| Creatinine clearance < 30 mL/min/m$^2$| 1.014661 | 0.08–1.94 | 0.033 |
| Left main coronary artery stenosis > 50% | 0.913525 | 0.1–1.7  | 0.026 |
| Moderate heart valve disease           | 1.109674 | 0.27–1.92 | 0.009 |
| Glucose > 150 mg/dL                    | 0.8668853| 0.02–1.7  | 0.044 |
| Constant                               | -3.623276| -4.6--2.6 | 0.000 |

https://doi.org/10.1371/journal.pone.0255662.t003

Table 4. Comparative evaluation of the calibration-in-the-large of ESII, STS and HiriSCORE models.

| Quintiles | ESII | STS | HiriSCORE |
|-----------|------|-----|-----------|
|           | Observed | Predicted | Observed | Predicted | Observed | Predicted |
| 1         | 14     | 5.2  | 12        | 0.8      | 3.7      | 4.18     |
| 2         | 14     | 5.61 | 2        | 1.3      | 8.51     | 7.07     |
| 3         | 12.24  | 6.4  | 4.08     | 1.6      | 10       | 12.6     |
| 4         | 12     | 7.2  | 21.57    | 2.2      | 20.41    | 16.5     |
| 5         | 14.29  | 8.81 | 27.08    | 3.9      | 31.71    | 35.19    |
| Mean      | 13.306 | 6.644| 13.346   | 1.96     | 14.866   | 15.108   |
| O−P       | 6.662  | 11.386| 0.242    |

O−P: observed minus predicted.

https://doi.org/10.1371/journal.pone.0255662.t004
Discrimination for ESII, STS and HiriSCORE models

As for discrimination, HiriSCORE model showed a satisfactory result of an area under the ROC curve (AUC) of 0.74 (95% CI 0.64–0.82). Analyzing traditional risk scores, we found that STS was better than ESII, obtaining a limit value of 0.67 (95% CI 0.62–0.72) against 0.50 (95% CI 0.58–0.69) of the AUC. It is important to emphasize that the literature considers good clinical models when the AUC is > 0.7 (Fig 3).
The HiriSCORE model showed a good AUC (0.74) while the STS and EuroSCORE II were poor in predicting mortality in high-risk patients undergoing CABG. Therefore, traditional scores were ineffective in discriminating mortality in high-risk patients.

**Discussion**

To date, there are no studies that assess the prediction of mortality risk in specific high-risk patients undergoing CABG. To estimate risk is to quantify complications that may occur after surgical procedures, allowing a better team planning, as well as decision-making and behavior regarding the procedures.

The two models with the most widespread use for cardiovascular surgery are STS and ESII. In addition, dissonant results appear throughout literature when applied in different scenarios [11–13]. However, evidence shows that, in patients considered to be at high risk for cardiac surgery, traditional scores lose accuracy in predicting mortality [14, 15].

This is probably because risk models originate from general populations of cardiac surgery patients, where most of them present low and medium risk and few are determined to be at high risk, especially in CABG surgeries [16]. For this scenario, procedure-specific models can be a solution for more accurate risk estimation for high-risk groups [17, 18]. Although the predictive variables for mortality after cardiac surgery are always the same, the most important is the weight of the coefficient given to each variable in relation to the specific outcome and group of patients. This is related to the degree of calibration of a model during the validation test. Therefore, calibration becomes the central phase for the validation of a risk prediction model, as it assesses how close the variable is to the outcome for such a scenario [18]. Thus, even with only a few variables, an instrument can be potential to predict mortality [19] and improve planning.

Perhaps the best idea for this scenario was launched by Ranucci in 2016 [20], adopting a two-stage approach for high-risk patients. Here, the high-risk population was underestimated by EuroSCORE II, therefore, patients with mortality risk above 25% were re-evaluated with more than 4 variables.

In this study, 5 predictors were defined. These predictors are partially involved in both, ESII and STS models, but with different coefficients. It shows the importance of reviewing the indication and re-stratifying patients with diabetes, overweight, renal dysfunction, significant left main coronary artery stenosis and moderate heart valve disease in patients referred for CABG.

Regarding the existing evidence in traditional models, Nashef et al [21] conducted a multicentric study that aimed to validate ESII using the STS database, and found similar observed and expected mortality, along with 0.77 in the model’s discriminative capability, reaching what the authors concluded to be an accurate result. Sergeant P. et al. [22] analyzed CABG patients using ESII, and the model reached a discriminative performance of 0.83, offering a good performance, but overestimating the risk in low-risk patients and underestimating it in high-risk patients. Yamaoka et al. [23] compared ESII to STS in the same sample and concluded that, regarding risk calibration, ESII was better, while STS overestimated risks. In this study, in the highest risk quartile, ESII showed excellent calibration and discrimination performance. In our study, calibration of the ESII was better than the STS, but discrimination was worse. One explanation can be the specific type of procedure evaluated.

Schrutka et al. reported the discriminatory power of scoring systems in patients treated with extracorporeal membrane oxygenation (ECMO) following cardiac surgery: both STS and ESII models showed low discriminatory accuracy in high-risk cohort [24]. The first Brazilian
validation of ESII is one study that ratifies our findings [25], where ESII was not well calibrated and underestimated the risk in high- and low-risk patients.

In 2020, Hu et al. performed a risk model for CABG patients based on the Chinese Cardiac Surgery Registry (CCSR) [26]. Compared with ESII and SinoSCORE, the CCSR model had better discrimination and calibration. As we can see, it includes 80% of the HiriSCORE variables.

Following this trend, we have compared the performance of HiriSCORE model to predict mortality in high-risk patients undergoing CABG. In this paper, we evaluated the performance of ESII and STS and compared them with the HiriSCORE model. Here, the predicted mortality by the STS was 2% and by the ESII was 6.6%, for the overall 13.3% observed mortality. The reclassification of patients leads to a change in medical concept about the best treatment strategy for the patient, considering alternatives such as percutaneous intervention or medical treatment. The better stratified patients, the greater the impact on medical practice.

Although for CABG the use of STS is still more recommended than ESII [27], our results disagree with its use in high-risk patients. Over time, the severity of patients referred for CABG increased [27], so it is essential to build and validate more accurate prediction models for planning, in addition to an open and transparent discussion with patients and family members.

In addition, Shahian et al. in 2018 reported that a limitation of the score is that STS database does not have data on high-risk patients [28]. On the other hand, the ESII database presented problems because up to 43% of patients presented biased information related to mortality [29].

Therefore, the presence of body mass index $> 30$ kg/m$^2$, glucose $> 150$ mg/dL, creatinine clearance $< 30$ mL/min/m, left main coronary artery stenosis and moderate heart valve disease become the simplest and best way to predict mortality in high-risk patients undergoing CABG.

**Study limitations**

First, as an international multicenter observational record, HiriSCORE project database had to be organized to avoid selection or definition bias. Therefore, the consolidated data had to be evaluated in relation to the consistency, accuracy, and completeness of the information, as well as monitoring the inclusion of patients and following up on the results. Second, ESII was used as an inclusion criterion for high-risk patients in the study. This may have influenced the results. However, the influence would be more in favor than against this model, and that is not what happened, which can further reinforce the evidence found. Third, it would be the 30-day mortality data of the discharged patients, since although the list was delivered by the participating hospitals, we were unable to check with the death verification system at the reference sites. Even understanding that complications in high-risk patients usually happen immediately after surgery.

**Conclusion**

The HiriSCORE model for high-risk patients undergoing CABG was better than STS and ESII. We encourage external validation of this model to be used by heart teams as an aid in making better strategy decisions in patients considered to be at high risk for CABG.

**Supporting information**

S1 Table. Characteristics of the final sample of patients from Brazil and China submitted to isolated CABG with ESII between 5–10%.

(DOCX)
Acknowledgments

We thank all the centers participating in this project for their commitment to the quality and safety of the patient.

Author Contributions

Conceptualization: Maxim Goncharov, Omar Asdrúbal Vilca Mejia, Camila Perez de Souza Arthur.

Data curation: Maxim Goncharov, Omar Asdrúbal Vilca Mejia, Camila Perez de Souza Arthur, Bianca Maria Maglia Orlandi.

Formal analysis: Maxim Goncharov, Omar Asdrúbal Vilca Mejia, Bianca Maria Maglia Orlandi.

Funding acquisition: Maxim Goncharov, Omar Asdrúbal Vilca Mejia, Bianca Maria Maglia Orlandi.

Investigation: Maxim Goncharov, Omar Asdrúbal Vilca Mejia, Camila Perez de Souza Arthur, Bianca Maria Maglia Orlandi.

Methodology: Maxim Goncharov, Omar Asdrúbal Vilca Mejia, Bianca Maria Maglia Orlandi.

Project administration: Maxim Goncharov, Omar Asdrúbal Vilca Mejia, Bianca Maria Maglia Orlandi, Alexandre Sousa, Marco Antônio Praça Oliveira, Fernando Antibas Atik, Rodrigo Coelho Segalote, Marcos Gradim Tiveron, Pedro Gabriel Melo de Barros e Silva, Marcelo Arruda Nakazone, Luiz Augusto Ferreira Lisboa, Luís Alberto Oliveira Dallan, Zhe Zheng, Shengshou Hu, Fabio Biscegli Jatene.

Resources: Maxim Goncharov, Omar Asdrúbal Vilca Mejia, Camila Perez de Souza Arthur, Bianca Maria Maglia Orlandi, Alexandre Sousa, Marco Antônio Praça Oliveira, Fernando Antibas Atik, Rodrigo Coelho Segalote, Marcos Gradim Tiveron, Pedro Gabriel Melo de Barros e Silva, Marcelo Arruda Nakazone, Luiz Augusto Ferreira Lisboa, Luís Alberto Oliveira Dallan, Zhe Zheng, Shengshou Hu, Fabio Biscegli Jatene.

Software: Maxim Goncharov, Omar Asdrúbal Vilca Mejia, Bianca Maria Maglia Orlandi.

Supervision: Omar Asdrúbal Vilca Mejia.

Validation: Maxim Goncharov, Omar Asdrúbal Vilca Mejia, Camila Perez de Souza Arthur, Bianca Maria Maglia Orlandi.

Visualization: Maxim Goncharov, Omar Asdrúbal Vilca Mejia, Alexandre Sousa, Marco Antônio Praça Oliveira, Fernando Antibas Atik, Rodrigo Coelho Segalote, Marcos Gradim Tiveron, Pedro Gabriel Melo de Barros e Silva, Marcelo Arruda Nakazone, Luiz Augusto Ferreira Lisboa, Luís Alberto Oliveira Dallan, Zhe Zheng, Shengshou Hu, Fabio Biscegli Jatene.

Writing – original draft: Maxim Goncharov, Omar Asdrúbal Vilca Mejia, Camila Perez de Souza Arthur, Alexandre Sousa, Marco Antônio Praça Oliveira, Fernando Antibas Atik, Rodrigo Coelho Segalote, Marcos Gradim Tiveron, Pedro Gabriel Melo de Barros e Silva, Marcelo Arruda Nakazone, Luiz Augusto Ferreira Lisboa, Luís Alberto Oliveira Dallan, Zhe Zheng, Shengshou Hu, Fabio Biscegli Jatene.

Writing – review & editing: Maxim Goncharov, Omar Asdrúbal Vilca Mejia, Camila Perez de Souza Arthur, Bianca Maria Maglia Orlandi, Fernando Antibas Atik, Rodrigo Coelho Segalote, Marcos Gradim Tiveron, Pedro Gabriel Melo de Barros e Silva, Marcelo Arruda
Nakazone, Luiz Augusto Ferreira Lisboa, Luis Alberto Oliveira Dallan, Zhe Zheng, Shengshou Hu, Fabio Biscegli Jatene.

References

1. McNeely C, Markwell S, Vassileva C. Trends in patient characteristics and outcomes of coronary artery bypass grafting in the 2000 to 2012 Medicare population. Ann Thorac Surg. 2016; 102:132–38. https://doi.org/10.1016/j.athoracsur.2016.01.016 PMID: 26941075

2. Mejia OA, Lisboa LA, Puig LB, Moreira LF, Dallan LA, Jatene FB. On-pump or off-pump? Impact of risk scores in coronary artery bypass surgery. Rev Bras Cir Cardiovasc. 2012; 27(4):503–11. https://doi.org/10.5935/1678-9741.20120091 PMID: 23515722

3. Englum BR, Saha-Chaudhuri P, Shahian DM et al. The impact of high-risk cases on hospitals’ risk-adjusted coronary artery bypass grafting mortality rankings. Ann Thorac Surg. 2015; 99:856–62. https://doi.org/10.1016/j.athoracsur.2014.09.048 PMID: 25983462

4. Shahian DM, O’Brien SM, Filardo G et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1—coronary artery bypass grafting surgery. Ann Thorac Surg. 2009; 88: S2–S22.

5. Nashef SA, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR et al. EuroSCORE II. Eur J Cardiothorac Surg. 2012; 41(4):34–44. https://doi.org/10.1093/ejcts/ezs043 PMID: 22378855

6. Gutacker N, Bloor K, Cookson R et al. Comparing hospital performance within and across countries: an illustrative study of coronary artery bypass graft surgery in England and France. Eur J Public Health. 2015; 25 Suppl 1:28–34.

7. Palma-Ruiz M, García de Dueñas L, Rodríguez-González A, Sarria-Santamara A. Analysis of inhospital mortality from coronary artery bypass grafting surgery. Rev Esp Cardiol. 2003; 56(7):687–94. https://doi.org/10.1016/s0300-8932(03)76940-1 PMID: 12855152

8. Akkerhuis KM, Deckers JW, Boersma E, et al. Geographic variability in outcomes within an international trial of glycoprotein Ilb/Ilia inhibition in patients with acute coronary syndromes. Results from PURSUIT. Eur Heart J. 2000; 21:371–81. https://doi.org/10.1053/euhj.1999.1743 PMID: 10666351

9. Howell NJ, Head SJ, Freemantle N, van der Meulen TA, Menon A et al. The new EuroSCORE II does not improve prediction of mortality in high-risk patients undergoing cardiac surgery: a collaborative analysis of two European centres. Eur J Cardiothorac Surg. 2013; 44:1006–11. https://doi.org/10.1093/ejcts/ezt174 PMID: 23536616

10. Shih T, Paone G, Theurer PF, McDonald D, Shahian DM, Prager RL. The Society of Thoracic Surgeons Adult Cardiac Surgery Database version 2.73: more is better. Ann Thorac Surg. 2015; 100:516–21. https://doi.org/10.1016/j.athoracsur.2015.02.085 PMID: 26052059

11. Mejia OA, Lisboa LA, Dallan LA, Pomerantzef PM, Moreira LF, Jatene FB et al. Validation of the 2000 Bernstein-Parsonnet and EuroSCORE at the Heart Institute—USP. Rev Bras Cir Cardiovasc. 2012; 27(2):187–94. https://doi.org/10.5935/1678-9741.20120033 PMID: 22996968

12. Barili F, Pacini D, Capo A, Ardemagni E, Pellicciari G, Zanobini M, et al. Reliability of new scores in predicting perioperative mortality after isolated aortic valve surgery: A comparison with the society of thoracic surgeons score and logistic EuroSCORE. Ann Thorac Surg. 2013; 95(5):1359–44. https://doi.org/10.1093/annthorac/sst114 PMID: 23473650

13. Barroso e Silva PG, Baruzzi AC, Ramos DLea et al. Improving indicators in a Brazilian hospital through quality-improvement programs based on STS database reports. Braz J Cardiovasc Surg. 2015; 30(6):660–3. https://doi.org/10.5935/1678-9741.20150075 PMID: 26934408

14. Ranucci M, Castelvecchio S, Menicanti LA, Scolletta S, Biagioli B, Giomarelli P. An adjusted EuroSCORE model for high-risk cardiac patients. Eur J Cardiothorac Surg. 2009; 36:791–8. https://doi.org/10.1016/j.ejcts.2009.02.023 PMID: 19359191

15. Grant SW, Hickey GL, Dimarakis I et al. Performance of the EuroSCORE models in emergency cardiac surgery. Circ Cardiovasc Qual Outcomes. 2013; 6:178–185. https://doi.org/10.1161/CIRCOUTCOMES.111.00018 PMID: 23463809

16. LaPar DJ, Filardo G, Crosby IK, Speir AM, Rich JB, Kron IL, et al. The challenge of achieving 1% operative mortality for coronary artery bypass grafting: A multi-institution Society of Thoracic Surgeons Database analysis. J Thorac Cardiovasc Surg. 2014 Dec; 148(6):2686–96. https://doi.org/10.1016/j.jtcvs.2014.06.086 PMID: 25152473

17. Howell NJ, Head SJ, Freemantle N et al. The new EuroSCORE II does not improve prediction of mortality in high-risk patients undergoing cardiac surgery: a collaborative analysis of two European centres. Eur J Cardiothorac Surg. 2013; 44(6):1006–11. https://doi.org/10.1093/ejcts/ezt174 PMID: 23536616

18. Kappetein AP, Head SJ. Predicting prognosis in cardiac surgery: a prophecy? Eur J Cardiothorac Surg. 2012; 41(4):732–3. https://doi.org/10.1093/ejcts/ezs061 PMID: 22378850
19. Tu JV, Sykora K, Naylor CD. Assessing the outcomes of coronary artery bypass graft surgery: how many risk factors are enough? Steering Committee of the Cardiac Care Network of Ontario. *J Am Coll Cardiol.* 1997; 30(5):1317–23. https://doi.org/10.1016/s0735-1097(97)00295-7 PMID: 9350934

20. Ranucci M, Di Dedda U, Castelvecchio S, La Rovere M et al. In search of the ideal risk-scoring system for very high-risk cardiac surgical patients: a two-stage approach. *J Cardiothorac Surg.* 2016; 11:13. https://doi.org/10.1186/s13019-016-0405-3 PMID: 26782077

21. Nashef SA, Roques F, Hammill BG, Peterson ED, Michel P, Grover FL et al. EurpSCORE Project Group. Validation of European System for Cardiac Operative Risk Evaluation (EuroSCORE) in North American cardiac surgery. *Eur J Cardiothorac Surg.* 2002; 22:101–5. https://doi.org/10.1016/s1010-7940(02)00208-7 PMID: 12103381

22. Sergeant P, de Worm E, Meyns B. Single centre, single domain validation of the EuroSCORE on a consecutive sample of primary and repeat CABG. *Eur J Cardiothorac Surg.* 2001; 20(6):1176–82. https://doi.org/10.1016/s1010-7940(01)01013-2 PMID: 11717024

23. Yamaoka H, Kuwaki K, Inaba H, Yamamoto T, Kato T et al. Comparison of modern risk scores in predicting operative mortality for patients undergoing aortic valve replacement for aortic stenosis. *J Cardiol.* 2016; 68(2):135–40. https://doi.org/10.1016/j.jjc.2015.08.017 PMID: 26411253

24. Schrutka L, Rohmann F, Binder C, Haberl T, Dreyfuss B, Heinz G et al. Discriminatory power of scoring systems for outcome prediction in patients with extracorporeal membrane oxygenation following cardiovascular surgery. *Eur J Cardiothorac Surg.* 2019; pii: ezz040. https://doi.org/10.1093/ejcts/ezz040 PMID: 30789227

25. Lisboa LAF, Mejia OA, Moreira LF, Dallan LAO, Pomerantz PM, Dallan LRet al. EuroSCORE II e a importância de um modelo local, InsCor e o futuro SP-SCORE. *Rev Bras Cir Cardiovasc.* 2014; 29(1):1–8. https://doi.org/10.5935/1678-9741.20140004 PMID: 24896156

26. Hu Z, Chen S, Du J et al. An in-hospital mortality risk model for patients undergoing coronary artery bypass grafting in China. *Ann Thorac Surg.* 2020; 109(4):1234–42. https://doi.org/10.1016/j.athoracsur.2019.08.020 PMID: 31541633

27. Neumann FJ, Sousa-Uva M, Ahlsson A et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J.* 2019; 40(2):87–165. https://doi.org/10.1093/eurheartj/ehy394 PMID: 30165437

28. Shahian DM, Torchiana DF, Engelman DT, Sundt TM et al. Mandatory public reporting of cardiac surgery outcomes: The 2003–2014 Massachusetts experience. *J Thorac Cardiovasc Surg.* Elsevier Inc 2019; 158(1):110–24. https://doi.org/10.1016/j.jtcvs.2018.12.072 PMID: 30772041

29. Sergeant P, Meuris B, Pettinari M. EuroSCORE II, illum qui est gravitates magni observe. *Eur J Cardiothorac Surg.* 2012; 41(4):729–31. https://doi.org/10.1093/ejcts/ezs057 PMID: 22378851